Lymfactin® gene therapy with vascularized lymph node transfer reduces compression-free swelling and enhances quality of life in breast cancer-related lymphedema: Final Phase I trial results
This prospective multicenter study demonstrated that Lymfactin® with VLNT is safe and well tolerated. Although volume reduction was most evident in the first year, half of the patients reduced or discontinued compression use, and quality of life improved over long-term follow up.
Authors
- Maija Mäki
- Pauliina Hartiala (ORCID: https://orcid.org/0000-0002-7606-7813)
- Tiina Viitanen
- Kari K. Alitalo (ORCID: https://orcid.org/0000-0002-7331-0902)
- Erkki Suominen
- Outi Lahdenperä (ORCID: https://orcid.org/0000-0001-6002-0669)
- Anne Saarikko (ORCID: https://orcid.org/0000-0002-3933-0627)
- Marko Seppänen (ORCID: https://orcid.org/0000-0003-2106-9528)
- Juha Kiiski (ORCID: https://orcid.org/0000-0002-2526-7057)
- Susanna Pajula (ORCID: https://orcid.org/0000-0003-4569-8046)
- Ilkka Kaartinen (ORCID: https://orcid.org/0000-0001-9928-6931)
- Sinikka Suominen (ORCID: https://orcid.org/0000-0003-0306-8783)
Institutions
- University of Helsinki (FI)
- University of Turku (FI)
- Tampere University (FI)
- Helsinki University Hospital (FI)
- Turku University Hospital (FI)
- Wihuri Research Institute (FI)
- Turku PET Centre (FI)
- Tampere University Hospital (FI)
- Tampere University (FI)
Publication Details
- Journal
- Journal of Plastic Reconstructive & Aesthetic Surgery
- Published
- 2025-10-16
- DOI
- https://doi.org/10.1016/j.bjps.2025.10.013
- Citations
- 2
- Primary Topic
- Lymphatic System and Diseases
- Type
- article
- Field-Weighted Citation Impact
- 2.09